2025 年 09 月 15 日 行业深度研究 看好/维持 医药 医药 行业企稳向好，回暖曙光已现 走势比较 | 化学制药 | 无评级 | | --- | --- | | 中药生产 | 无评级 | | 生物医药Ⅱ | 中性 | | 其 他 医 药 医 | 中性 | | 疗 | | 相关研究报告 <<板块缩量高位震荡，关注创新药 BD 新 进 展 （ 附 原 料 药 中 报 总 结 ） (2025.09.08-2025.09.14)>>-- 2025-09-15 <<太平洋医药日报（20250912）： Ionis 在研 ASO 疗法 ION582 获突破 性疗法认定>>--2025-09-14 <<祥生医疗：业绩符合预期，创新管 线稳步推进 >>--2025-09-13 证券分析师：周豫 电话： E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 证券分析师：张崴 电话： E-MAIL：zhangwei@tpyzq.com 分析师登记编号：S1190524060001 报告摘要 收入保持稳定增长，利润同比快速提升。2025 年上半年，CXO 板块实 现营业收入 47 ...

Group 1 - Tianhua New Energy plans to acquire 75% equity of Suzhou Tianhua Times for 1.254 billion yuan, aiming to transfer lithium resource investment to the listed company and eliminate potential competition risks [1] - Wan'an Technology intends to invest 20 million yuan in Tongchuan Technology through capital increase, acquiring 2.72% equity, focusing on core components for robotics [2] - Bid Pharma shareholders plan to reduce their holdings by no more than 1% of the company's total shares within three months [3] Group 2 - Borui Data shareholders plan to reduce their holdings by no more than 5.4% of the company's total shares, with specific reductions from key personnel [4] - Tonglian Precision announces that shareholders intend to reduce their holdings by no more than 3% of the company's total shares through various trading methods [5] - Zhongchao Holdings signs a strategic cooperation agreement with Hefei Intelligent Robot Research Institute to collaborate on technology and industrial applications in robotics [6] Group 3 - Guodun Quantum plans to sign sales contracts with China Telecom Quantum Group, with expected amounts of 12.144 million yuan and 63.054 million yuan for different projects [7] - Jingjiawei signs a strategic cooperation agreement with Anchaoyun, ensuring compatibility between its GPU products and Anchaoyun's software, supporting high-performance cloud desktop solutions [8] - *ST Dongtong faces potential forced delisting due to significant violations, with stock risk warnings implemented following regulatory actions [9]

Summary of Key Points Core Viewpoint - On September 12, 18 listed companies disclosed share reduction plans, with no companies announcing share increases on that day [1]. Group 1: Companies and Their Reduction Plans - Mars Man plans to reduce shares by up to 2.94% by a concerted action of its controlling shareholder [2]. - Minfa Aluminum's shareholder Huang Tianhu plans to reduce shares by up to 1% [2]. - Hengtian Hailong's shareholder China Hengtian Group intends to reduce up to 3% of the company's shares [2]. - Zhiwei Intelligent's controlling shareholder Guo Xuhui plans to reduce up to 7.5 million shares [2]. - Peking University Medicine plans to reduce 3% of its shares [2]. - Jin'an Guoji's controlling shareholder Donglin Investment and its concerted parties plan to reduce up to 3% [2]. - *ST Yitong's shareholder plans to reduce up to 2.96% of the company's shares [2]. - International Composite's shareholder Yunnan Yunxi plans to reduce up to 1.5% of the company's shares [2]. - Donghua Software's controlling shareholder Xue Xiangdong plans to reduce up to 1.4% of the company's shares [2]. - Huali Group's controlling shareholder Hong Kong Junyao plans to reduce up to 1.5% of the company's shares [2]. - Warner Pharmaceutical's shareholder Xu Xiaoqiang has cumulatively reduced 1.2961 million shares from September 1 to September 12 [2]. - Bidder Pharmaceutical's shareholders plan to collectively reduce up to 1% of the company's shares [2]. - Borui Data's shareholders plan to collectively reduce up to 5.4% of the company's shares [2]. - Tonglian Precision's shareholders Shenchuang Investment and its concerted parties plan to reduce up to 3% of the company's shares [2]. - Juguang Technology's controlling shareholder and its concerted parties have recently reduced 868,800 shares [2]. - Huat Gas's shareholders plan to reduce up to 2% of the company's shares [2]. - Beileisong's shareholder Wang Qiaoqing plans to reduce up to 1% of the company's shares [2]. - New Classics' shareholder Chen Liping plans to reduce up to 1.2 million shares [2].

Group 1 - Dongcai Technology's high-speed electronic resin has gained attention due to the rising demand in the high-end server industry, benefiting from the development of artificial intelligence and computing power upgrades [1] - The company's products, including various types of resins, have been successfully supplied to major server systems of leading companies such as NVIDIA, Huawei, Apple, and Intel, marking a new growth point for the company [1] Group 2 - Shangwei New Materials announced that 60 days have passed since the offer acquisition notice, and Zhiyuan Hengyue has deposited 232 million yuan as a performance guarantee, currently working on compliance confirmation and share transfer procedures [2] - The acquisition offer remains unconfirmed and carries uncertainty [2] Group 3 - Tianpu Co., Ltd. will hold an investor briefing on September 16, 2025, to discuss matters related to the transfer of control, with participation from the chairman, financial director, independent directors, and financial advisors [3] Group 4 - Zhongchao Holdings signed a strategic cooperation agreement with Hefei Intelligent Robot Research Institute to collaborate on technology and industrial applications in intelligent robotics and aerospace lightweight alloy casting [4] Group 5 - Juguang Technology's controlling shareholder and actual controller, along with their concerted actions, reduced their holdings by 868,821 shares, decreasing their total shareholding from 16.70% to 15.73% [5] Group 6 - Huakang Clean has won a medical service construction project with a bid price of 131 million yuan [7] - Guodun Quantum plans to sign a sales contract with China Telecom Quantum Group [7]

毕得医药(688073.SH)发布公告，因股东自身流动性需求，股东李怡静、陈俊、李黎、杜鹃、李爱飞、 耿勇、蒋亚妹计划根据市场情况拟于本减持计划披露之日起3个交易日后的3个月内通过集中竞价方式减 持其所持有的公司股份，减持数量不超过公司总股本的1%。 ...

智通财经APP讯，毕得医药(688073.SH)发布公告，因股东自身流动性需求，股东李怡静、陈俊、李 黎、杜鹃、李爱飞、耿勇、蒋亚妹计划根据市场情况拟于本减持计划披露之日起3个交易日后的3个月内 通过集中竞价方式减持其所持有的公司股份，减持数量不超过公司总股本的1%。 ...

Core Viewpoint - Bid Pharma (688073.SH) announced a share reduction plan by several shareholders due to their liquidity needs, with a total reduction not exceeding 1.00% of the company's total share capital [1] Shareholder Reduction Details - Shareholder Li Yijing plans to reduce up to 227,854 shares, representing 0.25% of the total share capital [1] - Shareholder Chen Jun plans to reduce up to 136,395 shares, representing 0.15% of the total share capital [1] - Shareholder Li Li plans to reduce up to 136,395 shares, representing 0.15% of the total share capital [1] - Shareholder Du Juan plans to reduce up to 136,395 shares, representing 0.15% of the total share capital [1] - Shareholder Li Aifei plans to reduce up to 131,836 shares, representing 0.15% of the total share capital [1] - Shareholder Geng Yong plans to reduce up to 91,265 shares, representing 0.10% of the total share capital [1] - Shareholder Jiang Yamei plans to reduce up to 47,960 shares, representing 0.05% of the total share capital [1] Implementation Timeline - The reduction will occur within three months starting from three trading days after the announcement of the reduction plan, with prices determined by market conditions at the time of the reduction [1]

Group 1 - The core point of the news is that shareholders of Bid Pharma plan to reduce their holdings due to personal liquidity needs, with a total reduction not exceeding 1% of the company's total share capital [1] - Specific reduction details include: Li Yijing plans to reduce up to approximately 227,900 shares (0.25% of total share capital), Chen Jun up to approximately 136,400 shares (0.15%), Li Li up to approximately 136,400 shares (0.15%), Du Juan up to approximately 136,400 shares (0.15%), Li Aifei up to approximately 131,800 shares (0.15%), Geng Yong up to approximately 91,300 shares (0.1%), and Jiang Yamei up to approximately 48,000 shares (0.05%) [1] - The reduction price will be determined based on the market price at the time of the actual implementation [1] Group 2 - For the year 2024, Bid Pharma's revenue composition is entirely from the research and experimental development industry, accounting for 100% [2] - As of the latest report, Bid Pharma has a market capitalization of 6.4 billion yuan [3]

证券代码：688073 证券简称：毕得医药 公告编号：2025-078 上海毕得医药科技股份有限公司 关于 2025 年半年度报告的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海毕得医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日 在上海证券交易所网站（www.sse.com.cn）披露了《2025 年半年度报告》，经事 后核查，未准确填报募集资金使用进展说明。公司董事会及管理层高度重视，第 一时间组织财务人员进一步核查及确认，并对相关数据予以更正，具体更正信息 如下： 一、更正内容 1、"第五节重要事项"之"十二、募集资金使用进展说明"之"（一）募集 资金整体使用情况"。 单位：万元 | | | | | | | | | 截至 | 截至 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | 报告 | 报告 | | | | | ...

证券代码：688073 证券简称：毕得医药 公告编号：2025-080 上海毕得医药科技股份有限公司 2025 半年度募集资金存放与使用情况的专项报告（修订版） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《关于同意上海毕得医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]1885 号），公司首次向社会公开发 行人民币普通股（A 股）股票 1,622.9100 万股，每股面值 1.00 元，每股发行价 88.00 元。共计募集资金 1,428,160,800.00 元，扣除不含税承销和保荐费用 92,830,452.00 元（税款 5,569,827.12 元由公司以自有资金承担）后的募集资金为 1,335,330,348.00 元，已由主承销商海通证券股份有限公司于 2022 年 9 月 29 日 汇入本公司募集资金监管账户。另减除申报会计师费、律师费、用于本次发行的 信息披露费、发行手续费用及其他等与发行权益性证券直接相关的新增外部费用 26,331,482.94 元 ...